# Olaparib in Recurrent IDH-mutant Glioma

> **NCT03561870** · PHASE2 · COMPLETED · sponsor: **Hospices Civils de Lyon** · enrollment: 35 (actual)

## Conditions studied

- Recurrent IDH
- Mutant High Grade Glioma

## Interventions

- **DRUG:** Olaparib 150 MG

## Key facts

- **NCT ID:** NCT03561870
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-20
- **Primary completion:** 2021-11-08
- **Final completion:** 2021-11-24
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2025-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03561870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03561870, "Olaparib in Recurrent IDH-mutant Glioma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03561870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*